Detalles de la búsqueda
1.
Spongipyran Synthetic Studies. Total Synthesis of (+)-Spongistatin 2.
Tetrahedron
; 65(33): 6470-6488, 2009 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20161196
2.
Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity.
ACS Med Chem Lett
; 10(5): 737-742, 2019 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31097992
3.
Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold.
ACS Med Chem Lett
; 10(6): 893-898, 2019 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31223444
4.
Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity.
J Med Chem
; 62(22): 10204-10220, 2019 11 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-31638799
5.
Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Oncotarget
; 8(13): 21741-21753, 2017 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28423515
6.
Insonation facilitates plasmid DNA transfection into the central nervous system and microbubbles enhance the effect.
Ultrasound Med Biol
; 31(5): 693-702, 2005 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-15866419
7.
Amounts and compositional analysis of glycosaminoglycans in the tissue of fish.
Carbohydr Res
; 366: 25-32, 2013 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-23261779
8.
The Spongistatins: Architecturally Complex Natural Products-Part Two: Synthesis of the C(29-51) Subunit, Fragment Assembly, and Final Elaboration to (+)-Spongistatin 2 Financial support was provided by the National Institutes of Health (National Cancer Institute) through Grant CA-70329, a NIH Postdoctoral Fellowship to C.S.B., a Japan Society for Promotion of Science Fellowship to N.M., and a Royal Society Fulbright Fellowship to V.A.D. We also thank the Daiichi Pharmaceutical Co., Ltd, and the Tanabe Seiyaku Co., Ltd for financial support. Finally we thank Dr George T. Furst, Dr. Patrick J. Carroll, and Dr. Rakesh Kohli of the University of Pennsylvania Spectroscopic Service Center for assistance in securing and interpreting high-field NMR spectra, X-ray crystal structures, and mass spectra, respectively.
Angew Chem Int Ed Engl
; 40(1): 196-199, 2001 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-11169711
9.
The Spongistatins: Architecturally Complex Natural Products-Part Two: Synthesis of the C(29-51) Subunit, Fragment Assembly, and Final Elaboration to (+)-Spongistatin 2.
Angew Chem Int Ed Engl
; 40(1): 196-199, 2001 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29711943
10.
The Spongistatins: Architecturally Complex Natural Products-Part One: A Formal Synthesis of (+)-Spongistatin 1 by Construction of an Advanced ABCD Fragment Financial support was provided by the National Institutes of Health (National Cancer Institute) through Grant CA-70329, NIH Postdoctoral Fellowships to A.M.B. and W.H.M., a Japan Society for Promotion of Science Fellowship to N.M., and a Royal Society Fulbright Fellowship to V.A.D. We also thank the Daiichi Pharmaceutical Co., Ltd, and the Tanabe Seiyaku Co., Ltd for financial support. Finally we thank Dr. George T. Furst, Dr. Patrick J. Carroll, Dr. Rakesh Kohli, and Mr John Dykins of the University of Pennsylvania Spectroscopic Service Center for assistance in securing and interpreting high-field NMR spectra, X-ray crystal structures, and mass spectra.
Angew Chem Int Ed Engl
; 40(1): 191-195, 2001 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-11169710
11.
The Spongistatins: Architecturally Complex Natural Products-Part One: A Formal Synthesis of (+)-Spongistatin 1 by Construction of an Advanced ABCD Fragment.
Angew Chem Int Ed Engl
; 40(1): 191-195, 2001 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29711948
12.
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate.
Bioorg Med Chem
; 15(22): 7087-97, 2007 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17869116
13.
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 5: Carbon-substituted analogues at the C-2 position.
Bioorg Med Chem
; 14(6): 1993-2004, 2006 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16290941
14.
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: exploration of aromatic substituents.
Bioorg Med Chem
; 14(24): 8506-18, 2006 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16979895
15.
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Bioorg Med Chem Lett
; 13(23): 4205-8, 2003 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14623002
16.
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 4: Addressing the problem of poor stability due to photoisomerization of an acrylic acid moiety.
Bioorg Med Chem Lett
; 14(10): 2493-7, 2004 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-15109639
17.
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of potency in the pyridopyrimidine series through the application of a pharmacophore model.
Bioorg Med Chem Lett
; 14(2): 475-9, 2004 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-14698185
18.
Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.
Bioorg Med Chem Lett
; 13(16): 2755-8, 2003 Aug 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-12873508
19.
MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization.
Bioorg Med Chem Lett
; 13(23): 4201-4, 2003 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-14623001
Resultados
1 -
19
de 19
1
Próxima >
>>